0000000000021336
AUTHOR
Maria Maddalena Laterza
Final results of neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker in advanced pancreatic cancer patients treated with Nab-paclitaxel plus Gemcitabine.
e15737Background: Pancreatic cancer is the ninth most common cancer and the forth cause of cancer-related mortality worldwide. New regimens have increased overall survival, but it still remains ext...
Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis
Background. High neutrophil to lymphocyte ratio (NLR) has shown to be a predictor of poor outcomes in various malignancies, including pancreatic cancer. Methods. We assessed 70 consecutive pts with histologically confirmed mPC who received chemotherapy with nab-paclitaxel/gemcitabine at two different European oncologic centers between January 2012 and November 2015. Variables assessed for prognostic correlations included age ≥ 66, sex, Karnofsky PS score, primary tumor site, baseline CA19.9 level ≥ 59xULN, 12-week decrease of the CA19.9 level ≥ 50% from baseline, basal bilirubin level, baseline NLR, biliary stent implantation, and liver metastasis. Survival analyses were generated according…